Crain's New York Business, January 15, 2024

Page 1

CRAINSNEWYORK.COM I JANUARY 15, 2024

Hochul’s agenda: Housing, mental health care, transit By Nick Garber, Jacqueline Neber and Caroline Spivack

Gov. Kathy Hochul laid out a policy agenda for 2024 focused on mental health care, crime and housing, including proposals to extend and replace the 421-a tax break for housing construction, advance two new train lines in New York City, and

buy out flood-prone properties. The plans included in Hochul’s “State of the State” speech, delivered Jan. 9 in Albany, will guide her upcoming budget proposal as she and state lawmakers pursue deals on a wide range of laws in the coming weeks. Despite fiscal headwinds and political pressure, Hochul reiterated her opposition to raising taxes.

“Working together, we will provide a better life to New Yorkers, with a commonsense agenda focused on fighting crime, fixing our mental health system, and protecting New Yorkers’ hard earned money,” Hochul’s prepared speech reads. At the same time, she alluded to diminishing federal pandemic aid and vowed that the state “won’t spend money we don’t have.”

After taking a big swing on housing last year, both Hochul and the Legislature’s ambitions may be constrained this year by an upcoming election and looming budget deficits. The state must close a $4.3 billion gap this year, followed by bigger gaps of $9.5 billion and $7.7 billion in fiscal See AGENDA on Page 19

Pfizer is one of a few pharmaceutical companies developing a weight-loss pill, but setbacks have slowed its progress. | BUCK ENNIS

Bloated Pfizer missing out on weight-loss drug craze Investor optimism that the company’s pill could be the next big thing is dwindling as the firm fails to join the $100 billion anti-obesity market. | By Amanda D’Ambrosio Pfizer defied the odds when it invented the world’s first Covid-19 vaccine in under a year, saving millions of lives and generating billions in revenue. Now, there’s a new challenge the health care titan can’t seem to crack: a weight-loss pill. The Hudson Yards-based pharmaceutical giant is clamoring to get a piece of the estimated $100 billion anti-

obesity market. The class of weight-loss drugs, GLP-1 agonists, that includes blockbuster products like Ozempic, Wegovy, Mounjaro and Zepbound are currently only offered in an injectable format, and a handful of companies, including Pfizer, are racing to develop an oral version of See PFIZER on Page 22

Pfizer CEO Dr. Albert Bourla. | BLOOMBERG

VOL. 40, NO. 2 l COPYRIGHT 2024 CRAIN COMMUNICATIONS INC. l ALL RIGHTS RESERVED

P001_CN_20240115.indd 1

Floating public pool slated to become a reality next year.

As residential listings linger, auctions are slowly becoming a mainstream way to sell in New York.

GOTHAM GIG Engineer working to make passenger experience better at JFK Airport’s Terminal 1.

PAGE 3

PAGE 13

PAGE 23

1/12/24 6:02 PM


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.